Ileal Resection Tied to Higher CRC Risk in Crohn's Disease
Patients with Crohn's disease who undergo terminal ileum resection have a significantly higher risk of developing colorectal cancer (CRC) and colorectal polyps than those who do not undergo resection.
METHODOLOGY:
Up to 70% of patients with Crohn's disease undergo ileocecal resection, which increases colonic bile acid flux exposure and potentially promotes induction of tumorigenic pathways. However, the direct impact of terminal ileum resection on CRC risk in Crohn's disease remains uncertain.
Researchers conducted a retrospective cohort study (2005-2024) using U.S. electronic health record data from adults with Crohn's disease to assess the association between terminal ileum resection and CRC risk.
The primary outcome was the risk for CRC in patients with and without terminal ileum resection.
Secondary outcomes included the risk for CRC based on biologics use and colonic involvement, and risk for benign colonic polyps.
TAKEAWAY:
Researchers included 13,617 patients with Crohn's disease who underwent terminal ileum resection (mean age, 39.5 years; 51.3% female) and an equal number of matched controls without resection.
Terminal ileum resection was associated with a significantly higher risk for CRC (adjusted hazard ratio [aHR], 2.58; P < .001), which was consistent in both men (aHR, 4.23; P < .001) and women (aHR, 2.43; P < .01).
Elevated CRC risk persisted regardless of colonic involvement (P < .01).
CRC risk did not significantly differ between patients who received biologic therapy and those who were biologic naive.
Patients with resection also had a higher risk for nonmalignant colonic polyps (aHR, 1.11; P < .01), which was consistent in both men and women (P < .01 for both).
IN PRACTICE:
"Our findings highlight the need to reassess CRC surveillance strategies in patients with [Crohn's disease] post-[terminal ileum] resection. While current guidelines focus on inflammation-related risk, our results suggest that surgical history itself is an independent risk factor," the authors concluded.
SOURCE:
This study was led by Inas Mikhail, MD, Mayo Clinic, Jacksonville, Florida, and Omar Al Ta'ani, MD, Allegheny Health Network, Pittsburgh, Pennsylvania. It was published online in Inflammatory Bowel Diseases.
LIMITATIONS:
The retrospective design may introduce biases related to reporting, selection, and follow-up. Residual confounding factors may have persisted despite propensity score matching. Due to a lack of data on bile acid profile and inflammatory burden, it could not be determined whether dysregulation of bile acids was directly involved in CRC risk.
DISCLOSURES:
This study authors reported no specific funding or conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
31 minutes ago
- CBS News
Mosquitoes with West Nile virus were found in the Twin Cities metro — here's what you need to know
What you need to know about West Nile virus What you need to know about West Nile virus What you need to know about West Nile virus On Thursday, the Metropolitan Mosquito Control District said they found mosquitoes in Anoka and Carver counties with West Nile virus. "The mosquito-borne disease risk tends to elevate as we get late into the summer," said Alex Carlson of the Metropolitan Mosquito Control District. That's why infectious disease experts say precautions are important. "West Nile virus has been circulating in Minnesota for over 20 years," said Dr. Beth Thielen, an infectious disease expert with M Health Fairview and the University of Minnesota Medical School. "The most common presentation that comes to the hospital is some kind of neurological symptoms." For those who might worry, Thielen says if you get West Nile virus, it's definitely not a death sentence. "Most of the disease is actually not clinically apparent," Thielen said. She says that bug repellants with DEET and picaridin are proven to help you if you're out and about. "We see most mosquitoes are active in that dusk time period. Folks can limit their outdoor exposure time around that time," Thielen said. But if a bite pops up, just monitor for things like fever and rash, Thielen added. "I don't usually wear bug spray," Minneapolis resident Lilly Perkins said. "I don't get bumps because they don't bother me, but I guess I should start." For more information on West Nile virus, click here.
Yahoo
an hour ago
- Yahoo
The Blueberry Recall Just Got More Serious—Here's What To Know
When the Fourth of July rolls around, there's nothing we love more than concocting the perfect, summery sweet treat. However, before you turn to the fruit aisle to grab fresh, seasonal strawberries and blueberries to bring to life that festive American flag cake that's every Pinterest lover's dream or that refreshing fruit salad, think twice. The FDA has issued a recall of hundreds of boxes of blueberries. Here, everything we know and what you ought to know ahead of the holiday weekend. Back in early June, a recall was issued by Georgia-based company Alma Pak International LLC for hundreds of boxes of organic blueberries. As stated by the initial report, the recall came to be when, during routine testing, the product tested positive for Listeria monocytogenes. In total, 400 30-pound boxes were part of this recall, identifiable by Lot numbers 13325 G1060 and 13325 G1096. The voluntary recall stated that these products were shipped to one customer in North Carolina. Though it was on June 9 that this recall was first issued, on July 1, the FDA elevated this situation to a Class I threat. As stated by their website, a Class I recall is 'a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.' While there have yet to be any reports of people falling ill after consuming this particular recalled product, vigilance is key when it comes to food safety. Over the last year, listeria is the word that's been circulating when it comes to recalls, and the symptoms can range from mild to severe. According to the FDA's website, the less severe version of the illness is non-invasive and usually will result in side effects like nausea, vomiting, fever, aches and diarrhea. On the contrary, the invasive version can be fatal. 'Symptoms may include headache, stiff neck, confusion, loss of balance, and convulsions,' says the FDA website. 'Invasive listeriosis is a potentially life-threatening event, especially for newborns, adults over the age of 65, and those with weakened immune systems.' If you think you might have consumed contaminated food, it's best to see your healthcare provider and monitor symptoms. If you start to feel any of the symptoms listed above, seek medical guidance. In a statement to Newsweek, the company revealed that the recall was issued before blueberries even hit shelves, meaning no customers consumed these contaminated products, and therefore, no one was at risk. They continued, 'The company worked in close coordination with the U.S. Food and Drug Administration (FDA), the Georgia Department of Agriculture, and an independent food safety consultant to conduct a thorough investigation. Alma Pak International has implemented additional corrective actions and preventive controls to further strengthen its already rigorous food safety systems.' Looking for more trending stories? Click through below! Could '1969' Be the Next 'Yellowstone' Series? Rumors Fly About a Prequel Between '1944' and Today From Tax Breaks to Medicaid Cuts: What the 'Big Beautiful Bill' Means for Americans 50+ Paula Deen's 5 Favorite Fourth of July Recipes—Drinks, Desserts & Deviled Eggs, Oh My! (EXCLUSIVE)
Medscape
an hour ago
- Medscape
Digital Twins: Medicine's New Crystal Ball?
Digital twins are rapidly emerging as powerful tools in personalized medicine and beyond. In healthcare, they serve as virtual representations of a patient's body, body parts, specific organs, and systems, such as the circulatory and nervous systems. Functional modeling of the state and behavior of the body or its components has the potential to provide information for clinical and research applications. The goal is to simulate how an organ, system, or even the entire body responds to stimuli and circumstances of clinical relevance to the patient, thereby deriving useful conclusions. These models may be descriptive, predictive, prescriptive, or even generative, capable of filling in missing or unavailable data. A central challenge is accurately replicating the physicochemical, physiological, anatomical, and, when needed, psychological attributes relevant to each specific use case. Building clinically useful digital twins depends on integrating diverse data sources, which is a technically complex task. However, when successful, it enables a dynamic 'dialogue' with the model to evaluate its current state, forecast evolution, and simulate responses to interventions such as therapies. It is important to emphasize that digital twin simulations are tailored to individual patients — they do not represent a generic or archetypal patient but instead aim to create a personalized model for a specific individual. One example is a project led by the Spanish National Cancer Research Centre (CNIO), which is developing digital twins of women with advanced cancer using artificial intelligence. This initiative, titled 'High-Definition Oncology in Women's Cancer,' is part of the Precision Medicine Infrastructure Associated With Science and Technology program. These digital twins consist of multiple layers of information integrated into a single model that reflects reality for a specific application. In the aforementioned project, a wide range of data were incorporated into the digital twin models, spanning tumor metabolism, gene and protein expression, physiological indicators such as circadian rhythms, heart rate, and physical activity, emotional well-being, and conventional clinical data from diagnostics to treatment protocols. Adding more 'layers' of information enhances the model complexity and accuracy, enabling incremental improvements and expanded functionality. A notable innovation in this case is the biological clock model developed by the CNIO, which estimates a patient's biologic age. This can help assess whether biologic aging accelerates or slows during disease progression, providing insight into the effect of treatment. This may guide clinicians in adjusting treatment intensity or modifying therapeutic combinations according to the patient's evolving biologic state. The layers of information used and their integration are key aspects of each type of digital twin, ensuring that it is not only functional but also clinically relevant. In many ways, digital twins serve as 'maps,' both literal and figurative. In the most direct sense, they can guide the planning of physical interventions such as surgical procedures. Broader Applications In addition to simulating the effects of therapies, digital twins can model the natural progression of diseases and support long-term care planning. They may help anticipate the onset of certain conditions, particularly hereditary diseases, when risk factors are present but symptoms have yet to appear. These models offer valuable tools for proactive risk prevention and management. In the context of prevention, the ability to present a stronger, data-driven case — even if derived from simulations — could help persuade patients and improve adherence to preventive care guidelines. Integration With Medical Devices From a certain perspective, digital twins resemble a technology-driven 'crystal ball.' Once refined, these models could allow clinicians to explore alternative therapeutic scenarios and identify the most effective treatment strategies. This minimizes reliance on trial and error, enabling faster data-driven decisions in a controlled simulation environment, a kind of clinical sandbox. A key area of synergy lies between the digital twins and medical devices. Wearable technologies, for instance, can supply real-time or periodic health data that dynamically update a patient's digital twin. Conversely, digital twins can enhance the medical device field by enabling the optimization of device configurations or implant placements. Their integration into the body and potential physiological effects can be modeled and simulated in advance, allowing for more precise and personalized interventions. These models also help to synthesize and manage large volumes of complex data. By serving as intelligent filters, they reduce the cognitive load on clinicians, offering clear visualizations and simulations that support more confident decision-making, especially in complex or uncertain clinical situations. Applications and Regulatory Considerations Digital twins hold promise across a wide range of medical applications, from early diagnosis, prognosis, and personalized therapy selection to treatment monitoring and relapse prevention. In fields such as neurology, cardiology, and oncology, these models have already shown potential. Digital twins have already been applied in neurology, cardiology, and oncology. Focusing on Spain-based developments, two recent advances featured by Univadis Spain , a Medscape Network platform, stand out: One involves using digital twins for research on the human brain to uncover mechanisms linked to psychosis remission, and the other demonstrates the use of digital twin improvements in the diagnosis of premature ventricular contractions. While the field is evolving rapidly, it remains in its early stages. Although technical hurdles and regulatory complexities are expected, the long-term potential is significant. Digital twins could enable faster and safer evaluations of multiple treatment paths and support virtual experimentation in a risk-free environment. One major challenge is clinical validation. Digital twins must be tested with real-world longitudinal data and demonstrate that their predictions provide added value compared to current clinical guidelines. Equally crucial is the development of interoperable, cross-border data infrastructure that enables scalable, coordinated adoption across healthcare systems worldwide. A final and crucial aspect to consider is data privacy, ownership, and ethical use of digital twins. Beyond the data itself, fundamental questions arise about digital twin models: Who owns a person's digital twin? Should these models be transferable, and if so, under what conditions? Informed consent is central to addressing these issues and ensuring the responsible use of digital twin technologies in clinical practice. The use of digital twins in clinical trials is already being explored, and their potential extends further to medical training and patient education, particularly in explaining therapeutic options. As technology evolves, the range of future applications continues to expand.
